State Street SPDR S&P Biotech ETF XBI
Source: Yahoo Finance (opens in a new tab) Observed · 1 day ago Quotes may be delayed
- Expense ratio
- 0.35%
- Net assets
- $10.7B
- Holdings
- 161
- 12-month distribution yield
- 0.36%
- Asset class
- Equity
State Street SPDR S&P Biotech ETF (XBI) is an exchange-traded fund listed on NYSE Arca in the United States, issued by State Street. Its category is Equity · US (equity). Its last price was US$153.24 on 20 Oct 2026. Its expense ratio is 0.35% a year, from its prospectus dated 31 Oct 2025. It reported net assets of US$10.73 billion as of 30 Jun 2026. Its latest holdings report lists 161 holdings as of 30 Jun 2026. Over the last 12 months it paid distributions of US$0.55 a unit, a 12-month distribution yield of 0.36%, paid quarterly.
Fees
- Total annual operating expenses (gross)
- 0.35%
- Net, after fee waivers or reimbursements
- No waiver stated
- Management fee
- 0.35%
- Prospectus date
- 31 Oct 2025
- Filed with the SEC
- 24 Oct 2025
Size and reporting
- Net assets
- $10,734,887,977
- Total assets
- $11,368,075,742
- Holdings as of
- 30 Jun 2026
- Report made public
- 28 Aug 2026 (59 days after the month end)
Top holdings
Largest 25 of 161 positions, as of 30 Jun 2026. Weight is the percent of net assets the fund reported.
| # | Holding | Identifier | Weight | Value (USD) | Type | Country | Currency |
|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors State Street Navigator Securities Lending Portfolio II | US8574927062 | 5.87% | $630.6M | Short-term investment vehicles (cash funds) | United States | USD |
| 2 | Apogee Therapeutics Inc | US03770N1019 | 1.49% | $159.8M | Equity (common) | United States | USD |
| 3 | Moderna Inc | US60770K1079 | 1.41% | $151.6M | Equity (common) | United States | USD |
| 4 | Twist Bioscience Corp | US90184D1000 | 1.41% | $151.1M | Equity (common) | United States | USD |
| 5 | Oruka Therapeutics Inc | US6876041087 | 1.38% | $148.0M | Equity (common) | United States | USD |
| 6 | Kymera Therapeutics Inc | US5015751044 | 1.36% | $145.9M | Equity (common) | United States | USD |
| 7 | Viking Therapeutics Inc | US92686J1060 | 1.30% | $140.0M | Equity (common) | United States | USD |
| 8 | Praxis Precision Medicines Inc | US74006W2070 | 1.29% | $138.5M | Equity (common) | United States | USD |
| 9 | Erasca Inc | US29479A1088 | 1.27% | $136.4M | Equity (common) | United States | USD |
| 10 | Revolution Medicines Inc | US76155X1000 | 1.20% | $129.3M | Equity (common) | United States | USD |
| 11 | Rhythm Pharmaceuticals Inc | US76243J1051 | 1.20% | $129.0M | Equity (common) | United States | USD |
| 12 | CG oncology Inc | US1569441009 | 1.20% | $128.8M | Equity (common) | United States | USD |
| 13 | SELLAS Life Sciences Group Inc | US81642T2096 | 1.19% | $127.7M | Equity (common) | United States | USD |
| 14 | Vaxcyte Inc | US92243G1085 | 1.19% | $127.4M | Equity (common) | United States | USD |
| 15 | Dianthus Therapeutics Inc | US2528281080 | 1.18% | $127.0M | Equity (common) | United States | USD |
| 16 | Cytokinetics Inc | US23282W6057 | 1.18% | $126.5M | Equity (common) | United States | USD |
| 17 | Natera Inc | US6323071042 | 1.16% | $124.8M | Equity (common) | United States | USD |
| 18 | Scholar Rock Holding Corp | US80706P1030 | 1.16% | $124.2M | Equity (common) | United States | USD |
| 19 | Roivant Sciences Ltd | BMG762791017 | 1.16% | $124.0M | Equity (common) | Bermuda | USD |
| 20 | Mirum Pharmaceuticals Inc | US6047491013 | 1.16% | $124.0M | Equity (common) | United States | USD |
| 21 | Cogent Biosciences Inc | US19240Q2012 | 1.14% | $122.8M | Equity (common) | United States | USD |
| 22 | Ultragenyx Pharmaceutical Inc | US90400D1081 | 1.14% | $122.4M | Equity (common) | United States | USD |
| 23 | Travere Therapeutics Inc | US89422G1076 | 1.13% | $121.0M | Equity (common) | United States | USD |
| 24 | Alkermes PLC | IE00B56GVS15 | 1.11% | $119.0M | Equity (common) | Ireland | USD |
| 25 | Krystal Biotech Inc | US5011471027 | 1.10% | $118.5M | Equity (common) | United States | USD |
Breakdowns
Sums of reported weights over every position in the report. Totals can differ from 100% because of derivatives, borrowing and cash.
Asset type
| Type | Weight | Bar |
|---|---|---|
| Equity (common) | 99.86% | |
| Short-term investment vehicles (cash funds) | 5.91% | |
| Equity derivatives | 0.11% |
Country
| Country | Weight | Bar |
|---|---|---|
| United States | 100.75% | |
| Ireland | 1.24% | |
| Bermuda | 1.16% | |
| Netherlands | 1.03% | |
| Switzerland | 1.02% | |
| British Virgin Islands | 0.53% | |
| Canada | 0.16% |
Currency exposure
| Currency | Weight | Bar |
|---|---|---|
| US dollar (USD) | 105.88% |
Sector
| Sector | Weight | Bar |
|---|---|---|
| Health Care | 42.61% | |
| Health Technology | 3.29% |
Source: SEC Form N-PORT (opens in a new tab) Holdings as of
Distributions
- Paid in the last 12 months
- $0.5450
- 12-month yield
- 0.36%
- Frequency
- Quarterly
- Latest ex-date
- 22 Jun 2026
12-month yield = distributions per unit with an ex-date in the last 12 months ($0.5450) ÷ latest price ($153.24) × 100 = 0.36%. It looks back, so it is not a forecast; special distributions in the window are included.
Why a distribution yield is not the fund's return: yield vs total return
Distribution history table (10 payments)
| Ex-date | Amount per unit |
|---|---|
| 22 Jun 2026 | $0.1380 |
| 22 Dec 2025 | $0.4070 |
| 22 Sep 2025 | $0.0270 |
| 23 Jun 2025 | $0.0070 |
| 24 Mar 2025 | $0.0050 |
| 23 Dec 2024 | $0.0030 |
| 23 Sep 2024 | $0.0150 |
| 24 Jun 2024 | $0.1150 |
| 18 Dec 2023 | $0.0140 |
| 20 Jun 2023 | $0.0030 |
Filings and sources
- Form N-PORT report for June 2026 (opens in a new tab)
- Prospectus filing with the fee table (opens in a new tab)
- All SEC filings for this fund series (S000010018) (opens in a new tab)
- Nasdaq Trader symbol directory (opens in a new tab)
- Yahoo Finance quote and distributions (opens in a new tab)
- How the ETF figures are collected
Compare with
Largest funds in the same category:
- XBI and VTI Vanguard Morningstar Total Stock Market ETF
- XBI and VOO Vanguard S&P 500 ETF
- XBI and IVV iShares Core S&P 500 ETF
- XBI and QQQ Invesco QQQ Trust, Series 1